查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治療市場規模、份額和趨勢分析報告：按藥物類型、最終用戶、地區、分部預測2022-2030
市場調查報告書
商品編碼
1122252

非酒精性脂肪性肝炎治療市場規模、份額和趨勢分析報告：按藥物類型、最終用戶、地區、分部預測2022-2030

Non-Alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc), By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

非酒精性脂肪性肝炎治療市場增長和趨勢

Grandview Research 的最新報告顯示，到 2030 年，全球非酒精性脂肪性肝炎治療市場預計將達到 159.5 億美元。從 2022 年到 2030 年，預計將以 39.2% 的複合年增長率增長。非酒精性脂肪性肝炎 (NASH) 治療市場的主要動力是諾和諾德的 Ozempic、Intercept 的 Ocaliva 和 Inventiva 的 Ranifibranol 等藥物的推出。

由於無法獲得批准的藥物、高疾病負擔和復雜的診斷程序等因素，NASH 治療市場存在大量未滿足的需求。市場目前以□格列酮和維生素 E 等標籤外藥物為主。這些是全球該領域最廣泛使用的處方藥。然而，為了解決未得到滿足的機會，市場參與者正在大力投資研發活動，以開發治療 NASH 的新療法。目前有超過 50 個候選管道。

計劃在預測期內推出的後期管道候選藥物包括來自 Inventiva Pharma 的 Lanifibranor、來自 Intercept Pharmaceuticals 的 Oveticholic acid、來自 Galmed Pharmaceuticals Ltd. 的 Aramchol、來自 Novo Nordisk A/S 的 Semaglutide 和 Madrigal Pharmaceuticals, Inc.，包括 Resmeirom 等。其中，Intercept 的奧貝膽酸 (OCA) 和 Madrigal 的 resmethirom 是最熱門的藥物，與其他管道候選藥物相比，預計將較早進入。

研究表明，非酒精性脂肪性肝炎與肥胖和糖尿病密切相關。研究發現，大約 80% 的 NASH 患者肥胖。在美國和其他地方，CDC 2021 年的最新統計數據顯示，肥胖率高達 42%。我們也知道，美國、日本等國家是世界上非酒精性脂肪性肝炎患病率最高的國家，而這些國家的肥胖和糖尿病負擔也很重。所有這些因素將在整個預測期內推動 NASH 治療市場。

主要製藥公司的戰略舉措和快速通道指定等監管支持政策預計將進一步加速市場增長。2022 年 5 月，輝瑞 (Pfizer) 的肘部胃司他/cresacostat 組合獲得了快速通道指定。它是治療非酒精性脂肪性肝炎的潛在藥物組合之一。這種藥物名稱有助於藥物的臨床試驗過程。

肝活檢是診斷非酒精性脂肪性肝炎的金標準。由於這種診斷測試的侵入性，它僅用於有症狀的病例，導致全球平均 NASH 診斷率約為 20%。市場增長預計將受到非侵入性基於生物標誌物的非酒精性脂肪性肝炎診斷測試的阻礙。

非酒精性脂肪性肝炎治療市場報告亮點

維生素 E 和□格列酮（標籤外）是唯一的貢獻者，2021 年市場份額為 100%。這可能是由於沒有市場批准的藥物

2021年，零售和專業藥房佔63.8%的份額。零售和專業藥房非常適合 NASH 等慢性病，患者通常與家庭護理環境有關

北美主導了 NASH 療法的收入。這可以歸因於疾病意識的提高、更好的醫療保健設施以及比其他地區相對更高的治療率。

目錄

第一章 調查方法和範圍

  • 市場細分和範圍
    • 段範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 第一次調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法：產品流方法
  • 調查假設
  • 二級信息列表
  • 縮略語表
  • 目的

第二章執行摘要

  • 市場概況

3. 非酒精性脂肪性肝炎治療市場變量、趨勢和範圍

  • 繪製滲透率和增長前景
  • 監管狀況
  • 行業分析——波特五力
  • PESTEL 分析（政法、經濟學、技術）
  • 流行病學分析
  • 未滿足需求分析
  • 按階段進行管道分析

4 非酒精性脂肪性肝炎治療市場：細分分析，按藥物類型，2018-2030 年（百萬美元）

  • 非酒精性脂肪性肝炎治療市場：藥物種類波動分析
  • 維生素E和□格列酮
  • 奧貝膽酸 (OCA)
  • 雷尼布諾
  • 索馬魯□
  • 瑞斯美隆
  • 阿拉姆科爾
  • 塞尼克裡維巖
  • 其他

5 非酒精性脂肪性肝炎治療市場：細分分析，按最終用途，2018-2030 年（百萬美元）

  • 非酒精性脂肪性肝炎治療市場：最終用途變化分析
  • 醫院藥房
  • 零售和專業藥店
  • 其他

6. 非酒精性脂肪性肝炎治療市場：細分分析，按地區，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2021 年和 2030 年區域市場份額分析
  • 區域市場快照
  • 2021-2030 年市場規模、預測、收入、趨勢分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 西班牙
      • 法國
      • 意大利
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 韓國
      • 澳大利亞
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 多邊環境協定
      • 南非
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國

7. 非酒精性脂肪性肝炎治療市場：競爭分析

  • 主要市場參與者的最新發展和影響分析
    • 新產品發布
    • 併購
    • 夥伴關係和戰略合作
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商情況
    • 主要經銷商及渠道合作夥伴名單
  • 主要客戶
  • 2021 年主要參與者的市場份額分析
  • 上市公司
    • 公司市場分析
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 民營企業
    • 主要初創企業名單
    • 區域網絡圖
  • 公司簡介
    • Intercept Pharmaceuticals
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Galmed Pharmaceuticals
      • 公司簡介
      • 財務績效
      • 產品基準
    • Inventiva Pharma
      • 公司簡介
      • 財務績效
      • 產品基準
    • Novo Nordisk A/S
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • AbbVie Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Galectin Therapeutics Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Madrigal Pharmaceuticals
      • 公司簡介
      • 產品基準
    • NGM Biopharmaceuticals Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Bristol Myers Squibb
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Novo Nordisk A/S
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Gilead Sciences Inc
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68039-964-6

Non-Alcoholic Steatohepatitis Treatment Market Growth & Trends:

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 15.95 billion by 2030, according to a new report by Grand View Research, Inc. The industry is projected to expand at a CAGR of 39.2% from 2022 to 2030. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-Alcoholic Steatohepatitis Treatment Market Report Highlights:

  • Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with 100% share to the market in 2021. This can be attributed to the unavailability of approved drugs in the market
  • The retail and specialty pharmacies segment held a share of 63.8% in 2021. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
  • North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Non-Alcoholic steatohepatitis treatment market Variables, Trends, and Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory Landscape
  • 3.3 Industry Analysis - Porter's Five Forces
  • 3.4 PESTEL Analysis (Political & Legal, Economic, and Technological)
  • 3.5 Epidemiology Analysis
  • 3.6 Unmet need analysis
  • 3.7 Pipeline Analysis, by Phase

Chapter 4 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, by Drug Type, 2018 - 2030 (USD Million)

  • 4.1 Non-Alcoholic steatohepatitis treatment market: Drug Type Movement Analysis
  • 4.2 Vitamin E and Pioglitazone
    • 4.2.1 Vitamin E and Pioglitazone Market, 2018 - 2030 (USD Million)
  • 4.3 Obeticholic Acid (OCA)
    • 4.3.1 Obeticholic Acid (OCA) market, 2018 - 2030 (USD Million)
  • 4.4 Lanifibranor
    • 4.4.1 Lanifibranor Market, 2018 - 2030 (USD Million)
  • 4.5 Semaglutide
    • 4.5.1 Semaglutide Market, 2018 - 2030 (USD Million)
  • 4.6 Resmetirom
    • 4.6.1 Resmetirom Market, 2018 - 2030 (USD Million)
  • 4.7 Aramchol
    • 4.7.1 Aramchol Market, 2018 - 2030 (USD Million)
  • 4.8 Cenicriviroc
    • 4.8.1 Cenicriviroc Market, 2018 - 2030 (USD Million)
  • 4.9 Others
    • 4.9.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, by End-use, 2018 - 2030 (USD Million)

  • 5.1 Non-Alcoholic steatohepatitis treatment market: End-use Movement Analysis
  • 5.2 Hospital Pharmacies
    • 5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.3 Retail and Specialty Pharmacies
    • 5.3.1 Retail and Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 6.1 Definition & Scope
  • 6.2 Regional Market Share Analysis, 2021 & 2030
  • 6.3 Regional Market Snapshot
  • 6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
    • 6.4.1 North America
      • 6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 6.4.1.2 U.S.
      • 6.4.1.2.1 U.S. Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.1.3 Canada
      • 6.4.1.3.1 Canada Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.2 Europe
      • 6.4.2.1 Europe Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.2 UK
      • 6.4.2.2.1 UK Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.3 Germany
      • 6.4.2.3.1 Germany Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.4 Spain
      • 6.4.2.4.1 Spain Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.5 France
      • 6.4.2.5.1 France Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.2.6 Italy
      • 6.4.2.6.1 Italy Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.3 Asia Pacific
      • 6.4.3.1 Asia Pacific Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.2 Japan
      • 6.4.3.2.1 Japan Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.3 China
      • 6.4.3.3.1 China Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.4 India
      • 6.4.3.4.1 India Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.5 South Korea
      • 6.4.3.5.1 South Korea Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.3.6 Australia
      • 6.4.3.6.1 Australia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.4 Latin America
      • 6.4.4.1 Latin America Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.4.2 Brazil
      • 6.4.4.2.1 Brazil Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.4.3 Mexico
      • 6.4.4.3.1 Mexico Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.4.4 Argentina
      • 6.4.4.4.1 Argentina Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
    • 6.4.5 MEA
      • 6.4.5.1 MEA Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.5.2 South Africa
      • 6.4.5.2.1 South Africa Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.5.3 Saudi Arabia
      • 6.4.5.3.1 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
      • 6.4.5.4 UAE
      • 6.4.5.4.1 UAE Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

Chapter 7 Non-Alcoholic steatohepatitis treatment market: Competitive Analysis

  • 7.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 7.1.1 New Product Launches
    • 7.1.2 Mergers and Acquisitions
    • 7.1.3 Partnerships and Strategic Collaboration
  • 7.2 Company Categorization
    • 7.2.1 Innovators
    • 7.2.2 Market Leaders
  • 7.3 Vendor Landscape
    • 7.3.1 List of key distributors and channel partners
  • 7.4 Key Customers
  • 7.5 Key Company Market Share Analysis, 2021
  • 7.6 Public Companies
    • 7.6.1 Company market position analysis
    • 7.6.2 Competitive Dashboard Analysis
      • 7.6.1.1 Market Differentiators
  • 7.7 Private Companies
    • 7.7.1 List of key emerging companies
    • 7.7.2 Regional Network Map
  • 7.8 Company Profiles
    • 7.8.1 Intercept Pharmaceuticals
      • 7.8.1.1 Company overview
      • 7.8.1.2 Financial performance
      • 7.8.1.3 Product benchmarking
      • 7.8.1.4 Strategic initiatives
    • 7.8.2 Galmed Pharmaceuticals
      • 7.8.2.1 Company overview
      • 7.8.2.2 Financial performance
      • 7.8.2.3 Product benchmarking
    • 7.8.3 Inventiva Pharma
      • 7.8.3.1 Company overview
      • 7.8.3.2 Financial performance
      • 7.8.3.3 Product benchmarking
    • 7.8.4 Novo Nordisk A/S
      • 7.8.4.1 Company overview
      • 7.8.4.2 Financial Performance
      • 7.8.4.3 Product Benchmarking
      • 7.8.4.4 Strategic initiatives
    • 7.8.5 AbbVie Inc.
      • 7.8.5.1 Company overview
      • 7.8.5.3 Financial Performance
      • 7.8.5.4 Product benchmarking
      • 7.8.5.5 Strategic initiatives
    • 7.8.6 Galectin Therapeutics Inc.
      • 7.8.6.1 Company overview
      • 7.8.6.2 Financial performance
      • 7.8.6.3 Product benchmarking
      • 7.8.6.4 Strategic initiatives
    • 7.8.7 Madrigal Pharmaceuticals
      • 7.8.7.1 Company overview
      • 7.8.7.2 Product benchmarking
    • 7.8.8 NGM Biopharmaceuticals Inc.
      • 7.8.8.1 Company overview
      • 7.8.8.2 Financial performance
      • 7.8.8.3 Product benchmarking
      • 7.8.8.4 Strategic initiatives
    • 7.8.9 Bristol Myers Squibb
      • 7.8.9.1 Company overview
      • 7.8.9.2 Financial performance
      • 7.8.9.3 Product benchmarking
      • 7.8.9.4 Strategic initiatives
    • 7.8.10 Novo Nordisk A/S
      • 7.8.10.1 Company overview
      • 7.8.10.2 Financial performance
      • 7.8.10.3 Product benchmarking
      • 7.8.10.4 Strategic initiatives
    • 7.8.11 Gilead Sciences Inc
      • 7.8.11.1 Company overview
      • 7.8.11.2 Financial performance
      • 7.8.11.3 Product benchmarking
      • 7.8.11.4 Strategic initiatives 

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Incidence of Diseases
  • Table 4 Global Non-Alcoholic steatohepatitis treatment market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 6 Global Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 7 North America Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 9 North America Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 14 Europe Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 17 Germany Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Germany Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 19 UK Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 20 UK Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 21 France Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 22 France Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 23 Italy Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 24 Italy Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 25 Spain Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Spain Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 29 Asia pacific Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 30 Japan Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 31 Japan Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 32 China Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 33 China Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 34 India Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 35 India Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 36 South Korea Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 37 South Korea Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 38 Australia Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Australia Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 40 Latin America Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 41 Latin America Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 42 Latin America Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 43 Brazil Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 44 Brazil Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 45 Mexico Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 46 Mexico Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 48 Argentina Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 49 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 51 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 52 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 54 South Africa Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 55 South Africa Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)
  • Table 56 UAE Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)
  • Table 57 UAE Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Non-Alcoholic steatohepatitis treatment market Segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Non-alcoholic steatohepatitis treatment market snapshot
  • FIG. 10 Parent market outlook
  • FIG. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
  • FIG. 12 Penetration and growth prospect mapping
  • FIG. 13 Non-alcoholic steatohepatitis treatment market driver impact
  • FIG. 14 Non-alcoholic steatohepatitis treatment market restraint impact
  • FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • FIG. 16 Industry Analysis - Porter's Five Forces
  • FIG. 17 Strategy mapping
  • FIG. 18 Non- alcoholic steatohepatitis treatment market: Drug type outlook and key takeaways
  • FIG. 19 Non- alcoholic steatohepatitis treatment market: Drug type movement analysis & market share 2021 & 2030
  • FIG. 20 Vitamin E and Pioglitazone non-alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Obeticholic Acid non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Lanifibranor non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 23 Semaglutide non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 24 Resmetirom non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 25 Aramchol non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Cenicriviroc non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Others non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 28 Non- alcoholic steatohepatitis treatment market: End-use outlook and key takeaways
  • FIG. 29 Non- alcoholic steatohepatitis treatment market: End-use movement analysis & market share 2021 & 2030
  • FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 31 Retail and speciality pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 33 Non-alcoholic steatohepatitis treatment market: Regional outlook and key takeaways
  • FIG. 34 Regional outlook, 2021 & 2030
  • FIG. 35 North America
  • FIG. 36 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 37 U.S.
  • FIG. 38 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 39 Canada
  • FIG. 40 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 41 Europe
  • FIG. 42 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 43 UK
  • FIG. 44 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 45 Germany
  • FIG. 46 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 47 France
  • FIG. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 49 Italy
  • FIG. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 51 Spain
  • FIG. 52 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 53 Asia-Pacific
  • FIG. 54 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 55 Japan
  • FIG. 56 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • FIG. 57 China
  • FIG. 58 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 59 India
  • FIG. 60 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 61 South Korea
  • FIG. 62 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 63 Australia
  • FIG. 64 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 65 Latin America
  • FIG. 66 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 67 Brazil
  • FIG. 68 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 69 Mexico
  • FIG. 70 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 71 Argentina
  • FIG. 72 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 73 Middle East & Africa
  • FIG. 74 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 75 South Africa
  • FIG. 76 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 77 Saudi Arabia
  • FIG. 78 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 79 UAE
  • FIG. 80 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 81 Market differentiators
  • FIG. 82 Key company market share analysis, 2021
  • FIG. 83 Company market position analysis
  • FIG. 84 Competitive dashboard analysis
  • FIG. 85 Regional network map